Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings
- PMID: 1718128
- DOI: 10.1007/BF00293959
Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings
Abstract
Clinical, neurochemical and neuropathological findings on a case of late-infantile Gaucher disease with oculomotor apraxia, progressive myoclonus and prominent bulbar signs are reported. There was a marked increase in glucosylceramide in cerebral cortex and cerebellum; the increase was more in the range of that seen in the Norrbottnian type III than in type II Gaucher disease. Cerebral cortical changes were characterized by a band-like intraparenchymal accumulation of Gaucher cells in lamina IV with an accompanying astrogliosis. In the cerebellum, a focal severe loss of granule cells and a global loss of dentate nucleus neurons was recorded. Milder changes were seen in thalamus and brain stem where perivascular accumulation of Gaucher cells was present in all regions. The cerebral cortical changes resembled those seen in type II Gaucher disease and was much more marked than in the Norrbottnian type III, whereas the changes in the dentate nucleus were more severe than in both type II and type III. The phenotypic variability with different patterns of clinical symptoms and neuropathological changes in neuronopathic Gaucher disease is discussed.
Similar articles
-
Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.Acta Neuropathol. 1984;65(2):99-109. doi: 10.1007/BF00690463. Acta Neuropathol. 1984. PMID: 6524300
-
Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease.J Neurochem. 1982 Sep;39(3):709-18. doi: 10.1111/j.1471-4159.1982.tb07950.x. J Neurochem. 1982. PMID: 7097276
-
Type 2 and type 3 Gaucher disease: a morphological and biochemical study.Ann Neurol. 1986 Aug;20(2):223-30. doi: 10.1002/ana.410200208. Ann Neurol. 1986. PMID: 3752966
-
Norrbottnian type of Gaucher disease--clinical, biochemical and molecular biology aspects: successful treatment with bone marrow transplantation.Dev Neurosci. 1991;13(4-5):345-51. doi: 10.1159/000112184. Dev Neurosci. 1991. PMID: 1817041 Review.
-
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842. Int J Mol Sci. 2022. PMID: 35628652 Free PMC article. Review.
Cited by
-
Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.J Inherit Metab Dis. 2006 Dec;29(6):707-15. doi: 10.1007/s10545-006-0411-z. Epub 2006 Nov 2. J Inherit Metab Dis. 2006. PMID: 17080304
-
Imiglucerase in the treatment of Gaucher disease: a history and perspective.Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. Drug Des Devel Ther. 2012. PMID: 22563238 Free PMC article. Review.
-
Neurological effects of glucocerebrosidase gene mutations.Eur J Neurol. 2019 Mar;26(3):388-e29. doi: 10.1111/ene.13837. Epub 2018 Dec 13. Eur J Neurol. 2019. PMID: 30315684 Free PMC article. Review.
-
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.Hum Mol Genet. 2010 Mar 15;19(6):1088-97. doi: 10.1093/hmg/ddp580. Epub 2010 Jan 4. Hum Mol Genet. 2010. PMID: 20047948 Free PMC article.
-
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.PLoS One. 2020 Jan 13;15(1):e0227077. doi: 10.1371/journal.pone.0227077. eCollection 2020. PLoS One. 2020. PMID: 31929594 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical